来曲唑治疗绝经后晚期乳腺癌临床观察

Letrozole in the treatment of postmenopausal advanced breast cancer.

目的观察来曲唑治疗绝经后晚期乳腺癌的疗效和不良反应。方法42例雌激素或孕激素受体阳性或不明的绝经后晚期乳腺癌患者口服来曲唑每日一次，每次2．5mg，28天一周期，至少2周期。结果42例患者中，可评价疗效者42例。完全缓解（Ca）0例；部分缓解（PR）5例，占11．9％；稳定（SD）23例，占54．8％，其中SD≥6个月14例，占33．3％；临床获益CBR（CR＋PR＋SD≥6个月）19例，占45．2％；进展14例，占33．3％。肿瘤进展时间2月～58月，中位进展时间（TTP）10月。未出现严重不良反应。结论来曲唑治疗绝经后晚期乳腺癌疗效确切，不良反应轻微，耐受性好。

Objective To evaluate the efficacy and side effects of letrozole for postmenopausal patients with advanced breast cancer. Methords Forty - two patients with advanced breast cancer received 2. 5mg per day letrozole for more than 8 weeks. Results All patients were evaluable for efficacy and adverse effects, there was no complete response, 5 （11.9%） partial respense, 23 （54.8%） stable disease, 14 （33.3%） progressive disease, 19 （45.2% ） clinical benefit（ CR ＋ PR ＋ SD ≥6months）. The median time to progression （mTTP） was ten months（2 to 58 months ）. There was no severe side effect in all patients. Conclusion Letrozole is effective and well tolerated in the treatment of postmenopausal breast cancer.